FLI1 Circular RNA As Biomarkers for Tracking Disease Progression and As Potential Therapeutic Targets in Small Cell Lung Cancer.

Jiuwei Cui,Lingyu Li,Jifan Hu
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e20573
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e20573 Background: Small cell lung cancer (SCLC) is ranked as the most devastative type of human lung malignancies. We have found Friend leukemia virus integration 1 (FLI1) circular RNA (cFLI1) is aberrantly expressed in SCLC tissues and closely correlates with the malignant phenotype of SCLC. Here, we explored the clinical significance of cFLI1s in SCLC patients. Methods: Initially, Using RNA fluorescence in situ hybridization (FISH) and quantitative PCR, we evaluated the expression levels of cFLI1 in 56 primary SCLC tissues and 50 non-small cell lung cancer (NSCLC) tissues. Subsequently, We confirmed its clinical relevance in longitudinal analyses of serum exosome cFLI1s (exo-cFLI1s) levels across time of SCLC patients (n = 165). Results: We found that cFLI1 (derived from exon 4-2-3 of FLI1) was aberrantly upregulated in SCLC tissues compared with NSCLC tissues(p < 0.0001), and positive associated with lymph node metastasis(p < 0.01). Serum exo-cFLI1 was significantly upregulated in SCLC tissues compared with healthy individuals (p = 0.0221), and exo-cFLI1 level in patients with extensive stage SCLC was significantly higher than that in limited stage SCLC patients(p = 0.0014). SCLC patients with lower level of exo-cFLI1 experienced longer disease remissions than those with higher exo-cFLI1 level (p = 0.038). Through tracking at several time-points during the course of treatment, we found that serum level of exo-cFLI1 was significantly reduced compared with their baseline levels when the disease of SCLC patients were partial remission (PR) or complete remission (CR) after 6 courses of first-line chemotherapy(p = 0.018). Conclusions: cFLI1 level is closely correlated with clinical response of SCLC patients who were receiving ongoing chemotherapy, and cFLI1 may be a promising biomarker for tracking disease progression and serve as potential therapeutic targets of SCLC.
What problem does this paper attempt to address?